G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 5월 2024 - 6:50AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced the grant of inducement stock options
exercisable for 2,100 shares of G1’s common stock and 1,050
restricted stock units (RSUs) to one hired employee under the
Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity
Incentive Plan (the “Amended and Restated 2021 Plan”). These equity
awards were granted as an inducement material to the new employee
becoming an employee of G1 in accordance with Nasdaq Listing Rule
5635(c)(4).
The Amended and Restated 2021 Plan is used exclusively for the
grant of equity awards to individuals who were not previously
employees of G1 (or following a bona fide period of
non-employment), as an inducement material to such individual’s
entering into employment with G1, pursuant to Rule 5635(c)(4) of
the Nasdaq Listing Rules.
The stock options are exercisable at a price of $4.13 per share,
the closing price of G1’s common stock on May 1, 2024, the grant
date. The stock options have up to a ten-year term and vest over
four years, with 25% of the award vesting on the first anniversary
of the employee’s employment, and as to an additional 1/48th of the
shares monthly thereafter, subject to continued service through the
applicable vesting dates (subject to the terms and conditions of
the stock option agreement covering the grant). The RSUs have a
four-year term, with 25% of the award vesting on the first
anniversary of the grant date, and the remainder vesting 12.5%
semi-annually over the remaining three years, subject to continued
service through the applicable vesting dates (subject to the terms
and conditions of the RSU agreement covering the grant). The stock
options and RSUs are subject to the terms and conditions of the
Amended and Restated 2021 Plan.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage oncology biopharmaceutical company whose mission
is to develop and deliver next-generation therapies that improve
the lives of those affected by cancer, including the Company’s
first commercial product, COSELA® (trilaciclib). The Company is
also evaluating therapies in combination with cytotoxic therapies
and/or immunotherapy in areas of high unmet need including
triple-negative breast cancer and extensive stage small cell lung
cancer. G1’s goal is to provide innovative therapeutic advances for
people living with cancer. G1 is based in Research Triangle Park,
N.C. For additional information, please visit
http://www.g1therapeutics.com and follow us on X (formerly known as
Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contact:
Will RobertsCommunications OfficerVice President, Investor
Relations and Corporate Communications(919) 907-1944
wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
G1 Therapeutics (NASDAQ:GTHX)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024